The patent wars in the high tech space get a lot of coverage, between lawsuits from so-called patent trolls to dustups between tech giants, there is rarely a shortage of news. But patent litigation in the pharma space is often a bit quieter, if only because it so often revolves around large drug makers suing companies that produce generic versions of certain medication.
But now, a battle over hepatitis C treatments has roped in several large drug manufacturers. The patent litigation stems from Gilead Sciences, which developed a hepatitis C treatment called Sovaldi. Now the company is going after three of its rivals: Merck, AbbVie and Roche.